The National Institute for Health and Clinical Excellence (NICE) has issued a guideline on the management of bedwetting (nocturnal enuresis) in children and young people.

With respect to pharmacological management, initial treatment should be with desmopressin, and some of the following recommendations have been made (taken directly from source, but please see link to full guidance for comprehensive list):

1. Offer desmopressin to children and young people over 7 years, if:
• rapid-onset and/or short-term improvement in bedwetting is the priority of treatment or
• an alarm is inappropriate or undesirable

2. Consider desmopressin for children aged 5–7 years if treatment is required and:
• rapid-onset and/or short-term improvement in bedwetting is the priority of treatment or
• an alarm is inappropriate or undesirable.

3. Do not exclude desmopressin as an option for the management of bedwetting in children and young people who also have daytime symptoms. However, do not use desmopressin in the treatment of children and young people who only have daytime wetting.

4. In children and young people who are not completely dry after 1 to 2 weeks of the initial dose of desmopressin (200 micrograms for Desmotabs or 120 micrograms for DesmoMelt), consider increasing the dose (to 400 micrograms for Desmotabs or 240 micrograms for DesmoMelt).
5. Assess the response to desmopressin at 4 weeks and continue treatment for 3 months if there are signs of a response. Consider stopping if there are no signs of response.

The guideline also discusses the roles of anticholinergics and tricyclic antidepressants following failure of desmopressin.

Please see link to the guidance for full details.